[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-lymphedema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-lymphedema":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,79,105,128,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":36,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053937","screening-for-bcrl-in-targeted-therapy-for-breast-cancer-100053937",false,"NCT05142800","Screening For BCRL In Targeted Therapy For Breast Cancer","Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer","Inclusion Criteria:\n\n* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF\u002FHCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.\n* Subjects that will be eligible for the study include:\n* Females between 18 and 80 years of age\n* With a history of breast cancer\n* 4 weeks or more post-surgery\n* With or without edema\n* Undergoing treatment with targeted therapy for early or metastatic disease.\n\nExclusion Criteria:\n\n\\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).","FEMALE","18 Years","80 Years",{"count":20,"type":21},261,"ESTIMATED","OBSERVATIONAL","This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.\n\nA Perometer and Sozo devise will be used to measure volume changes",[25,26,27,28,29,30,31,32,33,34,35],"Lymphedema","Lymphedema Arm","Lymphedema of Upper Arm","Lymphedema of Upper Limb","Lymphedema of the Hands","Edema","Edema Arm","Breast Cancer Lymphedema","Breast Cancer Metastatic","Breast Cancer Stage","Breast Cancer",[25,26,27,28,29,30,31,32,33,34,35],"RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2018-12-13",{"date":45,"type":21},"2026-09-30",{"name":47,"class":48},"Massachusetts General Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100637656","preoperative-indocyanine-green-lymphography-and-high-frequency-ultrasound-as-predictors-of-lymphaticovenous-anastomosis-outcome-in-post-mastectomy-upper-limb-lymphedema-100637656","NCT07614815","Preoperative Indocyanine Green Lymphography and High-Frequency Ultrasound as Predictors of Lymphaticovenous Anastomosis Outcome in Post-Mastectomy Upper Limb Lymphedema","Inclusion Criteria:\n\n* • Female patients aged 18 to 75 years.\n\n  * Unilateral secondary upper limb lymphedema following mastectomy with axillary lymph node dissection.\n  * Minimum interval of six months from completion of oncological treatment (surgery, radiotherapy, systemic therapy) to enrollment.\n  * ISL clinical stage I or II at the time of enrollment; late stage II eligible if patent lymphatic vessels are identified on preoperative HFUS.\n  * Provision of written informed consent (prospective phase).\n\nExclusion Criteria:\n\n* Bilateral upper limb lymphedema.\n\n  * Active locoregional or distant oncological recurrence.\n  * Prior lymphatic surgery on the affected limb.\n  * Severe peripheral vascular disease.\n  * Pregnancy or planned pregnancy during the study follow-up period.\n  * Documented hypersensitivity to indocyanine green or iodine","ALL","75 Years",{"count":59,"type":21},30,"INTERVENTIONAL",[62],"NA","This study aims to evaluate the predictive value of preoperative indocyanine green (ICG) lymphography and high-frequency ultrasound in determining the outcomes of lymphaticovenous anastomosis (LVA) in patients with post-mastectomy upper limb lymphedema. Patients undergoing LVA surgery will undergo preoperative assessment using ICG lymphography and ultrasound mapping of lymphatic vessels and recipient veins. Surgical outcomes will be assessed clinically and functionally through limb circumference measurements, symptom improvement, and postoperative imaging findings. The study seeks to identify imaging predictors associated with successful LVA outcomes and improved postoperative recovery.",[26,32],[66,67,68],"lymph-venous-anastamosis","ICG","HFUS","NOT_YET_RECRUITING","2026-05-22",{"date":72,"type":41},"2026-05-29",{"date":74,"type":21},"2026-05-27",{"date":76,"type":21},"2028-06-01",{"name":78,"class":48},"Assiut University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":86,"targetDuration":4,"studyType":60,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100602706","ilr-to-prevent-brclmcc-23608-100602706","NCT07127003","ILR to Prevent BRCL_MCC 23608","Prospective, Randomized Clinical Trial for Immediate Lymphatic Reconstruction to Prevent Breast Cancer Related Lymphedema","Inclusion Criteria:\n\n* Patients consenting for unilateral ALND \\[prior history of sentinel lymph node biopsy (SLNBx) allowed if \\\u003C6 months from consent\\]\n* Patients consenting for unilateral SLNBx with possible ALND, with a clinically or radiographically positive lymph node OR a high likelihood of ALND per the Breast Surgeon\n* Identification of at least one transected lymphatic channel and at least one vein to be used for bypass at the time of ALND during surgery\n* Female breast cancer patients 18-75 years of age (inclusive)\n\nExclusion Criteria:\n\n* • Male breast cancer patients\n\n  * Non-English speaking participants\n  * Female breast cancer patients with axillary recurrence\n  * Female breast cancer patients who have a history of ALND\n  * Female patients requiring bilateral ALND for the treatment of their breast cancer\n  * Female breast patients treated with SLNBx only\n  * Primary lymphedema of the affected upper limb\n  * Secondary lymphedema of the affected limb prior to the lymphadenectomy\n  * Radiotherapy at the axilla before the study \u002F surgery\n  * Life expectancy \\\u003C 2 years for any reason\n  * Pregnancy or nursing\n  * Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening\n  * Severe psychiatric disease\n  * Distant metastases at the time of preoperative screening",{"count":87,"type":21},98,[62],"The goal of this clinical trial is to evaluate the effectiveness of Immediate Lymphatic Reconstruction (ILR) in preventing breast cancer-related lymphedema (BCRL) in high-risk patients. It will also assess the safety and quality of life outcomes associated with the procedure. The main questions it aims to answer are:\n\nDoes ILR reduce the incidence of BCRL in patients undergoing axillary lymph node dissection (ALND)?\n\nWhat are the patient-reported outcomes and quality of life differences between those who receive ILR and those who do not?\n\nParticipants will be identified as high-risk for developing BCRL through a multidisciplinary tumor board and referred to a specialized clinic for further evaluation. High-risk patients will undergo a series of screening tests, including bioimpedance spectroscopy (BIS), circumferential limb measurements, and infrared 3D perometry.\n\nParticipants will be randomly assigned to one of two groups:\n\nIntervention Group (Study Arm A): Undergo ILR during ALND surgery, where preserved lymphatic channels are connected to nearby veins to prevent lymphedema.\n\nControl Group (Study Arm B): Will not receive ILR, but efforts will be made to preserve lymphatic channels during surgery.\n\nPatients will be blinded to their group assignment. Post-surgery, all participants will receive education from a certified lymphatic physical therapist.\n\nAt the 2-week postoperative visit, participants will be further randomized into two postoperative monitoring protocols:\n\nBCRL Clinical Pathway: Patients will have regular follow-up visits every three months for two years, including repeat BIS, limb measurements, perometry, and quality of life questionnaires (LYMQOL and ULL-27).\n\nStandard of Care: Patients will be monitored only if they experience BCRL symptoms or after two years from ALND.\n\nThe study will compare the outcomes of both groups, with a focus on the incidence of BCRL and patient quality of life, and will benchmark these results against published literature on breast cancer patients.",[32],[92,93,94],"Axillary lymph node dissection","breast cancer","lymphedema","2026-04-29",{"date":97,"type":41},"2026-04-30",{"date":99,"type":41},"2025-10-01",{"date":101,"type":21},"2027-10-01",{"name":103,"class":48},"University of South Florida",3,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":60,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":49},"100628303","effects-of-combined-upper-extremity-exercise-and-pneumatic-compression-therapy-on-breast-cancer-related-lymphedema-100628303","NCT07459881","Effects of Combined Upper Extremity Exercise and Pneumatic Compression Therapy on Breast Cancer-Related Lymphedema","Effects of Combined Upper Extremity Exercise and Pneumatic Compression Therapy on Breast Cancer-Related Lymphedema: A Prospective Single-Group Pilot Study","Inclusion Criteria:\n\n1. Female breast cancer patients aged 20-70 years\n2. Postoperative unilateral breast cancer surgery with a clinical diagnosis of lymphedema (stage I or II breast cancer treatment, with unilateral lymphedema greater than 2 cm and less than 8 cm at least one measurement point)\n3. Completion of subsequent chemotherapy\u002Fradiotherapy or other treatments at least 3 months postoperatively\n4. Ability to cooperate with 12 treatments and all assessments and sign a consent form\n\nExclusion Criteria:\n\n1. Breast cancer with a tendency for recurrence or metastasis\n2. Severe infection of the upper limb (cellulitis)\n3. Uncontrolled heart failure, deep vein thrombosis (DVT), severe peripheral vascular disease\n4. Stage III lymphedema, bilateral lymphedema, or need to take medications that may affect sweat glands in the upper limbs\n5. Other musculoskeletal disorders of the upper limbs, joint deformities, or a history of surgery\n6. Pregnancy or other conditions unsuitable for participation","20 Years","70 Years",{"count":115,"type":21},20,[62],"Breast cancer is one of the most common cancers among women worldwide. With advances in treatment, survival rates have steadily increased; however, postoperative complications continue to affect patients' quality of life, with upper extremity lymphedema being among the most prevalent. Breast cancer related lymphedema (BCRL) can result in arm swelling, pain, restricted mobility, and psychological distress, all of which negatively impact daily functioning and social partici pation .\n\nPrevious studies have demonstrated that regular and moderate upper extremity exercise does not exacerbate lymphedema; instead, it may improve shoulder mobility, muscular strength, and contribute to edema control. In addition, therapeutic modalities such as pneumatic compression pumps and manual lymphatic drainage have been proven effective in reducing swelling and enhancing patient comfort . Recent systema tic reviews further support the beneficial effects of exercise interventions on upper limb function and quality of life in breast cancer survivors.\n\nTherefore, combining upper extremity exercise with pneumatic compression therapy may re present a promising integrative intervention to improve lymphedema and related functional limitations. This study aims to investigate the effects of such a combined approach on breast cancer patients with lymphedema by comparing outcomes across multiple ti me points, including arm circumference measurements, shoulder range of motion, upper extremity function (DASH), and quality of life (FACT B), with the goal of establishing a more comprehensive rehabilitation model.",[32],"2026-03-03",{"date":121,"type":41},"2026-03-10",{"date":123,"type":21},"2026-03",{"date":125,"type":21},"2027-12",{"name":127,"class":48},"Far Eastern Memorial Hospital",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":60,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":49},"100494983","lllt-for-bcrl-a-randomized-placebo-controlled-study-100494983","NCT05725265","LLLT for BCRL: a Randomized, Placebo-controlled Study","Large-area Low-level Laser Therapy for Breast Cancer-related Lymphedema: a Randomized, Placebo-controlled Study","Inclusion Criteria:\n\n* Female subjects, 20 years age or older, suffered from unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection)\n* Stage I or II unilateral secondary upper extremity lymphedema(as defined by the International Society of Lymphology)\n* Girth≥ 2 cm circumferential difference compared with the uninvolved upper extremity at any 4 cm segment\n* Able to commit to a long-term follow-up schedule\n\nExclusion Criteria:\n\n* Metastatic cancer(stage IV)\n* Pregnancy\n* Presence of other extremity lymphedema (primary or secondary)\n* History of deep vein thrombosis\n* Pacemaker\n* Artificial joints, implant or tattoo(area≥4 cm2) at the involved upper extremity\n* Previous treatment with low-level laser therapy (within 3 months)\n* Body mass index (BMI) \\> 35 (morbid obesity)\n* High bleeding tendency(hemophilia)\n* Receiving long-term steroid treatment (oral or systemic)",{"count":136,"type":21},54,[62],"This study is conducted to compare between efficacy of large and small area of low-level laser therapy (LLLT) in treatment of post mastectomy lymphedema. The change of severity of BCRL will be measured by the difference of circumference and skin thickness, detected by ultrasound. The influence on clinical symptoms, such as pain, shoulder mobility and hand function, are also investigated in the study.",[32],[32,25,141,142],"Breast cancer","Low level laser therapy","2024-10-16",{"date":145,"type":41},"2024-10-18",{"date":147,"type":41},"2023-10-24",{"date":149,"type":21},"2025-10-31",{"name":151,"class":48},"National Taiwan University Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":60,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":49},"100524814","lymphatic-response-to-resistance-exercise-in-breast-cancer-survivors-100524814","NCT06113627","Lymphatic Response to Resistance Exercise in Breast Cancer Survivors","Prevention-Related Lymphatic Response to Resistance Exercise in Breast Cancer Survivors at Risk of Breast Cancer-Related Lymphedema","LinfoGYM","Inclusion Criteria:\n\n* Women diagnosed with breast cancer\n* Being of legal age\n* Histologically confirmed primary Breast Cancer (I-IIIA) (without the presence of metastasis) with a diagnosis in the last year\n* Unilateral involvement\n* Surgery for the tumor at least 6 weeks before the start of the intervention\n* WHO performance status of 0 (asymptomatic, complete and ambulatory activity)\n* Correct understanding of Spanish\n* Approval by signing the informed consent;\n* Mus be considered at risk for developing LACM: 1) Have undergone surgery that includes axillary dissection; 2) Have received or are undergoing regional lymph node radiation; 3) BMI \\>30 kg\u002Fm2. . These patients are considered to have stage 0, subclinical or latent according to the International Society of Lymphology (ISL) , since they will not present signs or symptoms, but lymphatic transport will be altered by the treatments themselves\n\nExclusion Criteria:\n\n* Women already diagnosed with LACM in stage I, II or III according to the ISL or if they present an L-Dex ratio \\> 10 or a difference in volume equal to or greater than 10% between both extremities\n* Suffer from or have been diagnosed with any other lymphatic-venous disease in the upper extremity, such as venous insufficiency, thrombosis or lipedema;\n* Suffer from conditions that prevent resistance exercise of the upper body\n* Participation in regular (\\>1 time\u002Fweek) and intense exercises involving the upper extremity during the last month\n* Suffer from heart disease\n* Inability to complete questionnaires;\n* A physical condition that prevents them from making hospital visits\n* Taking any drug that may affect the lymphatic and circulatory system, such as diuretics or corticosteroids\n* Women which presents some type of wound or infection on the skin.",{"count":161,"type":21},170,[62],"The objective of this study is 1) to study the acute and chronic effect of resistance therapeutic physical exercise (RTPE) in the prevention of breast cancer-related lymphedema (BCRL) in breast cancer survivors at risk using variables related to the lymphatic response; 2) Study the possible relationship between changes in body composition at a local and regional level and volume changes produced by RTPE in patients at risk of suffering from BCRL.",[32,165,28],"Survivorship",[35,167,32,168,169,170,171,172],"Lymphedema, Early-Onset","Exercise Therapy","Exercise Training","Acute Exercise","Exercise Movement Techniques","Physiotherapy (Techniques)","2023-10-30",{"date":175,"type":41},"2023-11-02",{"date":177,"type":21},"2024-08",{"date":179,"type":21},"2027-01-15",{"name":181,"class":48},"University of Malaga"]